MRTX-849， The Chinese name is adagrasib, and the English name is adagrasib. It is a mutation selective KRAS 12C covalent inhibitor with potential anti-tumor activity.

Adagracilib is used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults carrying KRAS G12C mutations. This is based on its demonstrated therapeutic effects on this type of tumor in clinical trials, including tumor shrinkage and improved disease control.

The cysteine residue 12 in the MRTX-849 molecular structure covalently binds to KRAS G12C, locking the protein in an inactive GDP binding conformation and inhibiting KRAS dependent signal transduction.

MRTX-849 is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with KRASG12C mutations who have received at least one systemic therapy in the past.

MRTX849 is an effective, selective, and covalent KRAS G12C inhibitor with excellent drug like properties, capable of selectively modifying mutated cysteine 12 in GDP bound KRAS G12C and inhibiting KRAS dependent signaling.